GRN-1201 / BrightPath Biotherap - LARVOL DELTA

GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC (clinicaltrials.gov) - P2 | N=20 | Terminated | Sponsor: BrightPath Biotherapeutics | Trial completion date: Oct 2023 ➔ Dec 2022 | Active, not recruiting ➔ Terminated; Recruitment rate too slow

IO biomarker • Metastases • Trial completion date • Trial termination • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HLA-A • PD-L1

GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC (clinicaltrials.gov) - P2 | N=20 | Active, not recruiting | Sponsor: BrightPath Biotherapeutics | Recruiting ➔ Active, not recruiting | N=64 ➔ 20 | Trial primary completion date: Oct 2022 ➔ Mar 2023

Enrollment change • Enrollment closed • IO biomarker • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HLA-A • IFNG • PD-L1

GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC (clinicaltrials.gov) - P2; N=64; Recruiting; Sponsor: BrightPath Biotherapeutics; Initiation date: Jun 2018 ➔ Jan 2019

Clinical • IO biomarker • Trial initiation date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer • PD-L1

GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC (clinicaltrials.gov) - P2; N=90; Recruiting; Sponsor: BrightPath Biotherapeutics; Not yet recruiting ➔ Recruiting; Initiation date: Mar 2018 ➔ Jun 2018

Clinical • Enrollment open • IO biomarker • Trial initiation date • Non Small Cell Lung Cancer • PD-L1

GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC (clinicaltrials.gov) - P2; N=64; Recruiting; Sponsor: BrightPath Biotherapeutics; Trial completion date: Mar 2021 ➔ Oct 2023; Trial primary completion date: Mar 2020 ➔ Oct 2022

Clinical • IO biomarker • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer • PD-L1

GRN 1201 (IASLC-LCTT 2020) - No abstract available